SCHEMBL2408699

SCHEMBL2408699

CS(=O)(=O)Nc1ccc(Cc2n[nH]c3c2c(=O)n(-c2ccccc2)c2ncccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.52
PDE1B Q01064 1/20 0.52
MAPK8 P45983 2/20 0.43
ENPP1 P22413 3/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
GAA P10253 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PDE4A P27815 7/20 0.41
PDE4B Q07343 6/20 0.41
PDE4C Q08493 6/20 0.41
PDE4D Q08499 6/20 0.41
FEN1 P39748 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
REN P00797 1/20 0.37
PARP1 P09874 1/20 0.36
GPR39 O43194 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2412397 0.92 PDE1A (0.46) PDE1APDE1BMAPK8ENPP1KDM4E
SCHEMBL2409616 0.88 PDE1A (0.54) PDE1APDE1BMAPK8ALDH1A1PDE4A
SCHEMBL2410839 0.87 PDE1A (0.66) PDE1APDE1BKDM4EALDH1A1PDE4A
SCHEMBL2409632 0.84 PDE1A (0.58) PDE1APDE1BMAPK8KDM4EALDH1A1
SCHEMBL2408474 0.84 PDE1A (0.58) PDE1APDE1BMAPK8KDM4EALDH1A1
SCHEMBL2409264 0.84 PDE1A (0.58) PDE1APDE1BMAPK8KDM4EALDH1A1
SCHEMBL2408536 0.83 PDE1A (0.55) PDE1APDE1BMAPK8ALDH1A1PDE4A
SCHEMBL2410183 0.82 PDE1A (0.56) PDE1APDE1BMAPK8ALDH1A1PDE4A
SCHEMBL2412520 0.82 PDE1A (0.56) PDE1APDE1BMAPK8PDE4APDE4B
SCHEMBL2409462 0.81 PDE1A (0.55) PDE1APDE1BMAPK8KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A PDE1A 28/4885PDE1B 24/4885MAPK8 1628/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A PDE1A 30/4885PDE1B 23/4885MAPK8 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.